After selling its spinout to Bayer in a $875M-plus deal, NeRRe Therapeutics grabs $28M for some 'unfinished business'

After selling its spinout to Bayer in a $875M-plus deal, NeRRe Therapeutics grabs $28M for some 'unfinished business'

Source: 
Endpoints
snippet: 

Some biotech CEOs find themselves out of jobs following a buyout. Not Mary Kerr.

In fact, after Bayer dished out $425 million in cash to buy KaNDy Therapeutics and its menopause treatment last August — which was spun out from NeRRe Therapeutics and run by that exact same team — her entire crew quickly got back to work.